00950 LEE'S PHARM
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 1.02X | Oper Margin | 8.1% |
|---|---|---|---|
| LT Debt/Equity | 4.2% | Net Margin | 6.7% |
| Total Debt/Equity | 13.8% | Return on Equity | 5.6% |
| Price/Book | 0.57X | Return on Assets | 3.6% |
| (HKD 1.600) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 93.10 | 16.70 | 51.28 | 1,987.18 | 129.32 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +457.6 | -67.4 | -97.4 | +1,436.7 | +3.0 |
| Earnings Per Share (HKD) | 0.158 | 0.028 | 0.087 | 3.376 | 0.22 |
| Earnings Per Share Growth (%) | +456.7 | -67.4 | -97.4 | +1,435.2 | +3.6 |
| Dividend Per Share (HKD) | 0.045 | 0.018 | 0.020 | 0.061 | 0.058 |
| P/E* (X) | 10.12 | 56.34 | 18.37 | 0.47 | 7.28 |
| Yield (%) | 2.81 | 1.13 | 1.25 | 3.81 | 3.63 |
| Dividend Share (%) | 28.46 | 63.38 | 22.96 | 1.81 | 26.38 |
| Book NAV (HKD) | 2.805 | 3.463 | 3.268 | 4.186 | 3.655 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (HKDMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 1,400 | 1,053 | +33.0 | 1,233 |
| Operating Result | 98.815 | -10.125 | -1,076.0 | 68.723 |
| Associates | -0.839 | -0.87 | -3.6 | -1.104 |
| Profit Before Taxation | 98.113 | 30.785 | +218.7 | 67.861 |
| Taxation | 29.501 | 10.836 | +172.2 | 22.026 |
| Profit /( Loss) After Taxation | 68.612 | 19.949 | +243.9 | 45.835 |
| Minority Interests | -24.487 | 3.251 | -853.2 | -5.449 |
| Net Profit | 93.099 | 16.698 | +457.5 | 51.284 |
| Earnings Per Share () | 0.1581 | 0.0284 | +456.7 | 0.0871 |
| Dividend Per Share () | 0.0450 | 0.0180 | +150.0 | 0.0200 |
| Announcement Date | 2025-03-27 | 2024-03-26 | NA | 2023-03-30 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
